bioRxiv Science⌕ Search

Biology subjects

Palou-Marquez, G.

Publications and source records attributed to Palou-Marquez, G..

2 recordsLinked to original sources

Allele-specific expression is selected in tumorigenesis, results from epigenetic changes and has prognostic relevance

Allelic imbalance (AI) in levels of mRNAs in cancer is widely appreciated to result from somatic copy number alterations (CNA) affecting one allele. Apart from CNA, other mechanisms could lead to imbalanced mRNA expression of the alleles, and similarly drive cancer evolution by epistatic interactions with the somatic mutations. By integrating genomic and transcriptomic pan-cancer data, we show that mRNA allelic imbalance favoring the mutant allele in driver genes is subject to positive selection, generating second-hit events often independently of somatic CNA. In some cases, the somatic coding mutations could induce allele-specific expression directly, e.g. with splicing-altering exonic mutations, which can be selected in various cancer genes. However, in the majority of cases, these and related somatic mutation effects (which might in principle alter transcription output via impacting promoters or intragenic enhancers) do not explain the CNA-independent mRNA-level AI, suggesting prevalent epigenetic alterations affecting alleles differently in tumors. Importantly, the mRNA AI events associate with worse overall survival across all cancer types, outperforming various other predictive markers. Our study suggests that mRNA allelic imbalances can occur independently of CNA but similarly function as second-hit events to somatic mutations, driving tumorigenesis, and so represent valuable prognostic biomarkers for cancer patient stratification.

cancer biology↗

Variable efficiency of nonsense-mediated mRNA decay across human tissues, tumors and individuals

Nonsense-mediated mRNA decay (NMD) is a quality-control pathway that degrades mRNA bearing premature termination codons (PTCs) resulting from mutation or mis-splicing, and that additionally participates in gene regulation of unmutated transcripts. We analyzed [~]10,000 exomes and [~]27,000 transcriptomes from human tumors and healthy tissues to quantify individual-level NMD efficiency, and assess its variability between tissues and between individuals. This was done by monitoring allele-specific expression of germline PTCs, and independently supported by mRNA levels of endogenous NMD target transcripts. Nervous system and reproductive system tissues have lower NMD efficiency than other tissues such as the digestive tract. Next, there is considerable systematic inter-individual variability in NMD efficiency, and we identify two underlying mechanisms. First, in cancers there are somatic copy number alterations that robustly associate with NMD efficiency, prominently the commonly-occurring gain at chromosome 1q that encompasses two core NMD genes: SMG5 and SMG7 and additional functionally interacting genes such as PMF1 and GON4L. Second, loss-of-function germline variants in various genes such as the KDM6B chromatin modifier can associate with higher or lower NMD efficiency in individuals, affecting different tissues thereof. Variable NMD efficiency should have clinical implications as it modulates positive selection upon somatic nonsense mutations in tumor suppressor genes, and is associated with survival of cancer patients, with relevance to predicting immunotherapy responses across cancer types.

genomics↗